Peptides
Evidence: animal_plus_anecdotal
P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.
Standard: Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
Maintenance: Research indicates 500-750 mcg daily.
Administration: intranasalsubcutaneous
Timing: Morning dosing preferred for cognitive effects.
Duration: 4-8 week cycles with 4-week rest periods.
P21 was developed to capture Cerebrolysin's neurogenic benefits in a small, BBB-permeable peptide — avoiding the need for IV infusion and the complexity of Cerebrolysin's 200+ peptide mixture. It promotes neurogenesis without the adverse effects of full-length CNTF (weight loss, fatigue). Efficacy demonstrated in normal cognitive enhancement, Alzheimer's models, TBI, and age-related decline. Community reports note improved memory consolidation and reduced brain fog.
Research-grade supplier only. Verify adamantylated glycine modification on COA.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →